Provided by Tiger Trade Technology Pte. Ltd.

iShares U.S. Healthcare ETF

71.17
-0.2000-0.28%
Post-market: 71.15-0.0200-0.03%19:30 EDT
Volume:313.32K
Turnover:22.29M
Market Cap:3.85B
PE:6.41
High:71.44
Open:71.17
Low:70.93
Close:71.37
52wk High:74.59
52wk Low:56.44
Shares:54.15M
Float Shares:54.15M
Volume Ratio:0.34
T/O Rate:0.58%
Dividend:0.80
Dividend Rate:1.12%
EPS(TTM):11.10
EPS(LYR):3.06
ROE:6.01%
ROA:0.87%
PB:1.38
PE(LYR):23.26

Loading ...

Leadership Departure and Flawed Compensation Clauses Cast Doubt on Ruifeng's Acquisition Deal

Deep News
·
4 hours ago

Health Advisory: Avoid Misusing Weight-Loss Medications, Prioritize Evaluation Before Treatment

Deep News
·
Yesterday

Retension Pharmaceuticals, TRex Bio File for US IPO as Biotech Momentum Continues

Reuters
·
Yesterday

3 ‘Strong Buy’ Dividend Aristocrat Stocks to Generate Steady Cash

TIPRANKS
·
Yesterday

Amneal Pharmaceuticals announces FDA approval and launch of Lanreotide

TIPRANKS
·
Yesterday

Sector Update: Healthcare

MT Newswires Live
·
Yesterday

US FDA Approves Lilly Inluriyo-Verzenio Combo for ESR1-Mutated Metastatic Breast Cancer

Reuters
·
Yesterday

U.S. FDA Approves Inluriyo (Imlunestrant) in Combination with Verzenio (Abemaciclib) for Adults with Er+, Her2-, Esr1-Mutated Advanced or Metastatic Breast Cancer

THOMSON REUTERS
·
Yesterday

Eli Lilly - Inluriyo with Verzenio NOW Available in the United States

THOMSON REUTERS
·
Yesterday

Exchange-Traded Funds, US Equities Lower After Midday

MT Newswires Live
·
Yesterday

Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Friday as Tech Rally Continues

MT Newswires Live
·
Sep 18

Personal Group Issues New Shares After PDMR Option Exercise

TIPRANKS
·
Sep 18

AbbVie presents new Vraylar data at Psych Congress 2026

TIPRANKS
·
Sep 18

AbbVie Says Real-World Studies Show Vraylar Improves Symptoms in MDD, Bipolar I Depression

Reuters
·
Sep 18

Abeona Therapeutics ‘congratulated’ Ultragenyx on U.S FDA approval of UX111

TIPRANKS
·
Sep 18

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), BioMarin Pharmaceutical (BMRN) and Axsome Therapeutics (AXSM)

TIPRANKS
·
Sep 18

Merck Says EU CHMP Backs Keytruda-Padcev Perioperative Use in Resectable Muscle-Invasive Bladder Cancer

Reuters
·
Sep 18

Merck & Co - Final Ec Decision Expected by Q4 2026

THOMSON REUTERS
·
Sep 18

Merck Receives Positive EU Chmp Opinion for Keytruda® (Pembrolizumab) Plus Padcev® (Enfortumab Vedotin-Ejfv) as Perioperative Treatment for Adults with Resectable Muscle-Invasive Bladder Cancer (Mibc)

THOMSON REUTERS
·
Sep 18

Merck Launches Your Hive of Whole Health to Support Whole Person Care for People Living with Hiv

THOMSON REUTERS
·
Sep 18